Literature DB >> 21037107

Confounding effects of hormone replacement therapy in protein biomarker studies.

Sharon J Pitteri1, Samir M Hanash.   

Abstract

BACKGROUND: We have recently investigated effects of hormone replacement therapy (HRT) on the serum proteome, and found a high proportion of proteins with altered levels associated with oral estrogen and/or estrogen plus progesterone treatment. Given this finding, we have investigated the extent to which exposure to HRT may have a confounding effect in the assessment of circulating proteins as cancer biomarkers.
METHODS: We utilize mass spectrometry data collected from the HRT serum proteome studies to estimate the overall effect of postmenopausal hormone therapy on candidate ovarian cancer biomarkers that have been previously reported.
RESULTS: Levels of approximately half of the proteins reported as potential ovarian cancer biomarkers were found to be affected by HRT. The impact of HRT on levels of insulin-like growth factor and inhibin protein families was found to be substantial.
CONCLUSIONS: We conclude that the potential confounding effect of HRT and other types of exposures should be taken into consideration in cancer biomarker study design. IMPACT: HRT significantly affects the serum proteome and should be taken into account as part of biomarker study design and data analysis. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21037107      PMCID: PMC4317711          DOI: 10.1158/1055-9965.EPI-10-0673

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  32 in total

Review 1.  Inhibins, activins and follistatin in reproduction.

Authors:  D M de Kretser; M P Hedger; K L Loveland; D J Phillips
Journal:  Hum Reprod Update       Date:  2002 Nov-Dec       Impact factor: 15.610

2.  Genome-wide identification of high-affinity estrogen response elements in human and mouse.

Authors:  Véronique Bourdeau; Julie Deschênes; Raphaël Métivier; Yoshihiko Nagai; Denis Nguyen; Nancy Bretschneider; Frank Gannon; John H White; Sylvie Mader
Journal:  Mol Endocrinol       Date:  2004-03-04

3.  An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.

Authors:  Ivo Meinhold-Heerlein; Dirk Bauerschlag; Yingyao Zhou; Lisa M Sapinoso; Keith Ching; Henry Frierson; Karen Bräutigam; Jalid Sehouli; Elmar Stickeler; Dominique Könsgen; Felix Hilpert; Constantin S von Kaisenberg; Jacobus Pfisterer; Thomas Bauknecht; Walter Jonat; Norbert Arnold; Garret M Hampton
Journal:  Clin Cancer Res       Date:  2007-01-15       Impact factor: 12.531

4.  A comparative longitudinal study on sex hormone binding globulin capacity during estrogen replacement therapy.

Authors:  S Helgason; J E Damber; M G Damber; B von Schoultz; G Selstam; R Södergård
Journal:  Acta Obstet Gynecol Scand       Date:  1982       Impact factor: 3.636

5.  Effects of transdermal and oral contraceptives on estrogen-sensitive hepatic proteins.

Authors:  Terry White; Begüm Ozel; John K Jain; Frank Z Stanczyk
Journal:  Contraception       Date:  2006-06-27       Impact factor: 3.375

6.  Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.

Authors:  Cynthia Kuk; Vathany Kulasingam; C Geeth Gunawardana; Chris R Smith; Ihor Batruch; Eleftherios P Diamandis
Journal:  Mol Cell Proteomics       Date:  2008-12-01       Impact factor: 5.911

7.  [Evaluation of selected serum protein markers as early detectors of ovarian cancer].

Authors:  Jolanta Mrochem; Krzysztof Sodowski; Regina Deja; Aneta Walaszek-Gruszka; Andrzej Wojcieszek; Zofia Kołosza; Aleksandra Chmura; Ewa Czernik; Barbara Masłyk; Wiesława Bartnik; Wojciech Cnota
Journal:  Ginekol Pol       Date:  2008-04       Impact factor: 1.232

8.  A serum based analysis of ovarian epithelial tumorigenesis.

Authors:  Brian Nolen; Adele Marrangoni; Liudmila Velikokhatnaya; Denise Prosser; Matthew Winans; Elesier Gorelik; Anna Lokshin
Journal:  Gynecol Oncol       Date:  2008-11-12       Impact factor: 5.482

9.  Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.

Authors:  Sharon J Pitteri; Lellean JeBailey; Vitor M Faça; Jason D Thorpe; Melissa A Silva; Reneé C Ireton; Marc B Horton; Hong Wang; Liese C Pruitt; Qing Zhang; Kuang H Cheng; Nicole Urban; Samir M Hanash; Daniela M Dinulescu
Journal:  PLoS One       Date:  2009-11-19       Impact factor: 3.240

10.  Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.

Authors:  Garnet L Anderson; Martin McIntosh; Lieling Wu; Matt Barnett; Gary Goodman; Jason D Thorpe; Lindsay Bergan; Mark D Thornquist; Nathalie Scholler; Nam Kim; Kathy O'Briant; Charles Drescher; Nicole Urban
Journal:  J Natl Cancer Inst       Date:  2009-12-30       Impact factor: 13.506

View more
  6 in total

1.  Proteomic profiling of the autoimmune response to breast cancer antigens uncovers a suppressive effect of hormone therapy.

Authors:  Timothy Chao; Jon J Ladd; Ji Qiu; Melissa M Johnson; Rebecca Israel; Alice Chin; Hong Wang; Ross L Prentice; Ziding Feng; Mary L Disis; Samir Hanash
Journal:  Proteomics Clin Appl       Date:  2013-05-10       Impact factor: 3.494

2.  Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.

Authors:  J W Pedersen; A Gentry-Maharaj; E-O Fourkala; A Dawnay; M Burnell; A Zaikin; A E Pedersen; I Jacobs; U Menon; H H Wandall
Journal:  Br J Cancer       Date:  2012-11-20       Impact factor: 7.640

3.  Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study.

Authors:  Annemieke W J Opstal-van Winden; Esmeralda J M Krop; Monica H Kåredal; Marie-Christine W Gast; Christian H Lindh; Marina C Jeppsson; Bo A G Jönsson; Diederick E Grobbee; Petra H M Peeters; Jos H Beijnen; Carla H van Gils; Roel C H Vermeulen
Journal:  BMC Cancer       Date:  2011-08-26       Impact factor: 4.430

4.  Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case–control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.

Authors:  Johannes W Pedersen; Aleksandra Gentry-Maharaj; Alexander Nøstdal; Evangelia-Ourania Fourkala; Anne Dawnay; Matthew Burnell; Alexey Zaikin; Joy Burchell; Joyce Taylor Papadimitriou; Henrik Clausen; Ian Jacobs; Usha Menon; Hans H Wandall
Journal:  Int J Cancer       Date:  2014-05-01       Impact factor: 7.396

5.  Epidermal growth factor receptor (EGFR) expression in the serum of patients with triple-negative breast carcinoma: prognostic value of this biomarker.

Authors:  Rogério Agenor de Araújo; Felipe Andrés Cordero da Luz; Eduarda da Costa Marinho; Camila Piqui Nascimento; Lara de Andrade Marques; Patrícia Ferreira Ribeiro Delfino; Rafael Mathias Antonioli; Breno Jeha Araújo; Ana Cristina Araújo Lemos da Silva; Maria Luiza Gonçalves Dos Reis Monteiro; Morun Bernardino Neto; Marcelo José Barbosa Silva
Journal:  Ecancermedicalscience       Date:  2022-07-20

6.  Assessing biological and technological variability in protein levels measured in pre-diagnostic plasma samples of women with breast cancer.

Authors:  Christine Y Yeh; Ravali Adusumilli; Majlinda Kullolli; Parag Mallick; Esther M John; Sharon J Pitteri
Journal:  Biomark Res       Date:  2017-10-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.